E. V. Kvasova

E. V. Kvasova

Auto-generated profile, based on publicly available information

E. V. Kvasova

Rostov Regional Clinical Diagnostic Center “Zdorovye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
TDT. V. Dubinina
T. V. Dubinina
ALAleksandr M Lila
Aleksandr M Lila
EKE. V. Kvasova
E. V. Kvasova
EAE. M. Agafonova
E. M. Agafonova
IAI. A. Andrianova
I. A. Andrianova
ЮГЮ. Ю. Грабовецкая
Ю. Ю. Грабовецкая
NiSpAR is a non-interventional, multicenter study whose aim was to describe a cohort of patients with non-radiological axial spondyloarthritis (nr-axSpA) and approaches to its diagnosis in the Russian Federation.Material and methods. The study involved 20 research centers in different regions of the Russian Federation. The work consisted of two phases: retrospective data collection 12 months before enrolment in the study and prospective observation of patients in whom the diagnosis of nr-axSpA was confirmed (104 weeks).The study included 272 patients who met the inclusion and exclusion criteria (Full Analysis Set, FAS). The mean age of the FAS-population was 38.7±11.0 years. The diagnosis of nr-axSpA was confirmed in 159 (58.5 %) of the 272 patients. Of the remaining 113 (41.5%) participants, 57 (50.4%) did not have the information required to confirm the diagnosis, 34 (30.1%) did not have pelvic radiographs, and 22 (19.5%) did not fulfil the ASAS criteria for nr-axSpA.Results and discussion. The mean age of patients with nr-axSpA was 37.6±10.4 years, more than half of them (52.8%) were women. The median disease duration was 36 [12; 80] months. In half of the patients the disease duration was more than 2 years, in more than one third – less than 2 years. The median CRP and ESR values were 5.0 [2.0; 12.0] mg/l and 11.0 [5.0; 18.0] mm/h, respectively. The BASDAI averaged 3.5±2.0 and was >4 in more than half of the cases (64.2%). The mean ASDAS-CRP value reached 2.6±1.1. Only 1 in 5 participants (20.8%) had low axSpA activity, while in 61.1% it was high (44.7%) or very high (16.4%). An inactive state was found in a small number of patients (9.4%). Twenty two (13.8%) patients had treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) in anamnesis, and 21 (13.2%) patients were still taking them.Conclusion. The results of the retrospective phase of the study show that in real-life clinical practice in the Russian Federation there is a continued positive trend towards improving the diagnosis of nr-axSpA. The median duration of the disease at the time of enrolment in the study was 3 years. The frequency of use of magnetic resonance imaging has increased by more than 1.8 times. At the same time, practitioners still have difficulties in establishing the diagnosis of nr-axSpA and a shortage of bDMARDs for treatment of these patients.

18 December 2022 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
OMO. N. Matveeva
O. N. Matveeva
EKE. V. Kvasova
E. V. Kvasova
In December 2019, the world faced a new infectious disease, called the novel coronavirus disease 2019 (COVID-19), whose spread has become pandemic. The infection that remains with us to the present day can cause very severe respiratory symptoms up to total lung damage and death, as well as serious systemic manifestations associated with excessive activation of immune mechanisms. Currently, there are many cases of secondary autoimmune processes, often forming full-fledged autoimmune diseases, in people who have had a new coronavirus infection.We present a clinical observation of episcleritis developed on the background of COVID-19, and then an articular syndrome onset that met the classification criteria for rheumatoid arthritis. The unusual debut of the articular syndrome in this patient, the difficulties of early diagnosis of the disease, as well as possible mechanisms of the formation of such associations are discussed.

17 August 2026 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
TDT. V. Dubinina
T. V. Dubinina
ALAleksandr M Lila
Aleksandr M Lila
EAE. M. Agafonova
E. M. Agafonova
IAI. A. Andrianova
I. A. Andrianova
EIE. V. Ilyinykh
E. V. Ilyinykh
VMV I. Mazurov
V I. Mazurov
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of <2 years was 54.6%. More than half of the patients were male (52.2%). HLA-B27 positivity was detected in 70.8% of cases. The mean BASDAI and ASDAS-CRP scores were 3.6±2.0 and 2.7±0.9, respectively. Before inclusion in the study, the vast majority of patients received nonsteroidal anti-inflammatory drugs (94.7%), predominantly coxibs (55.5%); the synthetic disease-modifying antirheumatic drugs (DMARDs) sulfasalazine and methotrexate were used in 20.4 and 9.7%, respectively, systemic glucocorticoids in 3.5%, and biologic diseasemodifying antirheumatic drugs (bDMARDs) 9.7%. Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.